Project Grant R01AG082373
- This three-year, $4.766 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, aims to clarify the neuropathological, molecular, and genetic differences between Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) through the Aging Research grant program (CFDA 93.866). The J. David Gladstone Institutes will use digital pathology, artificial intelligence, single-nuclei RNA sequencing, and spatial transcriptomics on...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $2,234,905.00 in funding to The University of Iowa to support research aimed at understanding the underlying mechanisms responsible for cognitive fluctuations in Lewy body disorders (LBD). The project will use mouse models to evaluate how the accumulation of...
- The National Institute on Aging (NIA) awarded a $400,707 Project Grant (CFDA 93.866 - Aging Research) to the University of Florida to map brain lipid architecture in aging, Lewy body dementia (LBD), and T-cell therapy. The 2-year grant, running from September 1, 2024 to August 31, 2026, will utilize novel imaging mass spectrometry to generate a spatial atlas of the lipidome and identify lipid markers of disease progression in LBD. The research aims to assess lipid alterations resulting from an...
- This $2,069,215 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research by Case Western Reserve University to investigate the role of the beta-arrestin2-LMBRD2 pathway in the transmission and toxicity of pathological alpha-synuclein, which is a defining hallmark of Lewy body diseases such as Parkinson's disease and dementia with Lewy bodies. The research will utilize cellular and animal models to study the mechanisms by which beta-arrestin2...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $732,992 to Virginia Commonwealth University to elucidate the role of cholinergic degeneration in cognitive fluctuations (CF) in Lewy body dementia (LBD). The project aims to determine the association between cholinergic degeneration and CF in LBD, using neuroimaging techniques...
- This Project Grant award of $414,191 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research by Drexel University investigating the relationship between structural variations in alpha-synuclein (α-syn) protein fibrils and the development of distinct neurodegenerative synucleinopathies such as Lewy body dementia, Parkinson's disease, and multiple system atrophy....
- This $1,707,089 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research by Northwestern University to investigate synergistic approaches for enhancing endoplasmic reticulum (ER) proteostasis, protein trafficking, and lysosomal activity as potential treatments for dementia with Lewy bodies and Parkinson's disease-dementia. The research will use patient-derived induced pluripotent stem cell neuron models and mouse models to test the effects of...
- This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) is providing $436,775 to Brandeis University to investigate how individual differences in the brain's dopamine system may contribute to resilience against Alzheimer's disease pathology. The key objectives of this 2-year research project are to: Determine if the DRD2 T/T genotype, associated with higher dopamine D2 receptor availability, confers greater cortical thickness despite the presence of...
- The National Institute on Aging (NIA) awarded a $717,491 Project Grant under its Aging Research program (CFDA 93.866) to New York University (NYU) School of Medicine to develop single domain antibodies (sdAbs) that can detect and clear alpha-synuclein (αSyn) in animal models of synucleinopathies. The project aims to evaluate the in vivo imaging potential, clearance mechanisms, and therapeutic efficacy of these sdAbs targeting αSyn, a key protein involved in neurodegenerative diseases like Lewy...
- The National Institute on Aging (NIA), within the U.S. Department of Health and Human Services, awarded a $457,875 project grant under the Aging Research federal grant program (CFDA 93.866) to the University of Connecticut Health Center. The grant will fund the development and characterization of the first LRP10 knockout mouse model to investigate the role of LRP10 in the pathogenesis of Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. The project aims to examine...
INTERSECTION OF GBA AND LRRK2 IN LEWY BODY DEMENTIA - LEWY BODY DEMENTIA (LBD) IS THE SECOND MOST COMMON FORM OF NEURODEGENERATIVE DEMENTIA, BEHIND ONLY ALZHEIMER'S DISEASE (AD). LBD IS CLINICALLY DEFINED AS A DEMENTIA THAT ARISES PRIOR TO OR WITHIN ONE YEAR OF A PARKINSON'S DISEASE (PD) DIAGNOSIS OR PD WITH SUBSEQUENT DEMENTIA. POST-MORTEM EXAMINATION OF LBD BRAINS COMMONLY REVEALS A COMBINED PATHOLOGY OF INTRANEURONAL LEWY BODIES ALONG WITH AMYLOID PLAQUES AND NEUROFIBRILLARY TANGLES CONSISTENT WITH AD. AS SUCH, LBD IS CONSIDERED ONE OF THE ALZHEIMER'S DISEASE AND RELATED DEMENTIAS (ADRDS). A SMALL SUBSET OF GENES IMPLICATED IN OTHER NEUROLOGIC DISEASES INFLUENCE RISK FOR LBD (E.G. GBA1, APOE), WHILE MANY GENES DETERMINANT FOR FAMILIAL FORMS OF AD OR PD DO NOT. THESE DATA SUGGEST A MEANINGFUL PARTIAL OVERLAP OF NEURODEGENERATIVE DISEASE GENES WITH REGARDS TO LBD. WHILE APOE HAS RECENTLY RECEIVED ATTENTION REGARDING ITS INFLUENCE ON BOTH AMYLOID AND ALPHA-SYNUCLEIN PATHOLOGY, GBA1 HAS NOT BEEN AS THOROUGHLY EXAMINED. AUTOSOMAL RECESSIVE MISSENSE MUTATIONS IN THE GBA1 GENE CAUSE THE LYSOSOMAL STORAGE DISORDER, GAUCHER'S DISEASE. INTRIGUINGLY, RECENT WORK DEMONSTRATES THAT GBA1 IS ALSO THE GREATEST RISK FACTOR FOR LBD. THE MOLECULAR MECHANISMS THROUGH WHICH GBA1 MUTATIONS MAY EVOKE THIS UNIQUE CLINICAL PRESENTATION AND COMPLEX NEUROPATHOLOGY ARE NOT KNOWN. OUR DATA DEMONSTRATE NOVEL GOLGI-RELATED DYSFUNCTION IN GBA1 MUTANT CELLS, UPSTREAM TO THE LYSOSOMAL AND LATE ENDOSOMAL EVENTS IMPORTANT TO ALPHA- SYNUCLEIN AND APP PROCESSING, RESPECTIVELY. HERE, WE WILL USE WILDTYPE INDUCED PLURIPOTENT STEM CELL-DERIVED NEURONS, AS WELL AS MATCHED ISOGENIC NEURONS HARBORING MULTIPLE PATHOGENIC GBA1 MUTATIONS, TO EXAMINE THE INFLUENCE OF GBA1 ON THE REGULATION, TRAFFICKING, AND MATURATION OF KEY LYSOSOMAL PROTEINS THOUGHT TO BE INVOLVED IN THE METABOLISM OF ALPHA-SYNUCLEIN. WE WILL ALSO EXAMINE THE RESULTING CHANGES IN ALPHA-SYNUCLEIN DEGRADATION AND NEURONAL RELEASE, AND THE ACCUMULATION OF ALPHA-SYNUCLEIN SPECIES RECENTLY DISCOVERED IN HUMAN LBD BRAIN TISSUE. IN ADDITION, THE EFFECT OF PATHOGENIC MUTATION IN GBA1 LINKED TO LBD ON GAMMA- SECRETASE AND APP BIOLOGY WILL BE MECHANISTICALLY AND PATHOLOGICALLY INTERROGATED HERE BOTH IN VITRO AND IN VIVO. LASTLY, EMERGING CLINICAL AND BIOCHEMICAL DATA DEMONSTRATE THAT GBA1 AND LRRK2 INTERACT IN BOTH PHYSIOLOGICAL AND DISEASE-RELEVANT WAYS. LRRK2 MUTATIONS CAUSAL FOR PD APPEAR TO DECREASE RISK OF DEMENTIA IN GBA1 PATIENTS. THUS, TO MODEL THESE DUAL-MUTATION CARRIERS, WE WILL EXAMINE NEURONS WITH GBA1 MUTATION ALONE OR THOSE ALSO EXPRESSING PATHOGENIC LRRK2 MUTATIONS AND ASSESS PATHWAYS RELEVANT TO SYNUCLEINOPATHY AND AMYLOIDOGENESIS DESCRIBED ABOVE. THIS WORK WILL DIRECTLY INVESTIGATE NOVEL PATHWAYS WITH THE POTENTIAL TO UNDERSTAND THE NOVEL CLINICAL PHENOTYPES AND MIXED AD/PD PATHOLOGY IN LBD. OUR APPROACH EXPLOITS THE GENETIC AND MOLECULAR INTERSECTIONS OF MULTIPLE NEURODEGENERATIVE DISEASES WITH THE GOAL OF UNDERSTANDING BOTH THE SIMILARITIES AND DIFFERENCES IN THEIR ETIOLOGIES.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $46.3k | 6/18/25 | ||
| Not listed | $520.5k | 4/9/25 | ||
| Not listed | $520.5k | 4/9/25 | ||
| Not listed | $560.5k | 7/15/24 | ||
| Not listed | $560.5k | 7/15/24 |